Introduction {#Sec1}
============

Parathyroid hormone (PTH) stimulates bone formation and resorption and can increase or decrease bone mass, depending on the dose and timing of administration. Continuous infusions and daily subcutaneous injections of teriparatide stimulate bone formation but have distinct effects on bone resorption and bone mass \[[@CR1], [@CR2]\]. Daily injections of 20 and 40 μg teriparatide increased the bone mineral density (BMD) at the lumbar spine by 9 and 13 %, and reduced the risk of incident vertebral fractures by 65 and 69 % as relative risk reduction, respectively, as compared with placebo \[[@CR3]\].

Weekly injections of 56.5 μg teriparatide have been shown to increase BMD at the lumbar spine by 8.1 % after 48 weeks of treatment as determined by dual energy X-ray absorptiometry (DXA) \[[@CR4]\]. Anti-fracture efficacy of once-weekly subcutaneous injection of 56.5 μg teriparatide for 72 weeks was evaluated in 578 postmenopausal women and older men with primary osteoporosis by a randomized controlled trial, the Teriparatide Once-Weekly Efficacy Research (TOWER) trial \[[@CR5]\]. Vertebral fracture risk was reduced by 80 % as relative risk reduction.

Daily treatment with teriparatide reduced the risk of non-vertebral fractures by 35 to 40 % at the 20 and 40 μg dose, respectively, and reduced the risk of non-vertebral fragility fractures by 53 and 54 %, respectively \[[@CR3]\]. Weekly treatment with teriparatide reduced the risk of clinical fragility fractures include non-vertebra by 67 % \[[@CR5]\].

The bone geometry in the proximal femur is thought to be strongly related to bone strength, and our previous studies showed that proximal femur geometrical parameters could predict the incidence of neck fracture or inter-trochanter fracture \[[@CR6]\].

The reason for reduced risk of non-vertebral fracture may be explained by changes in structure and biomechanical properties by teriparatide treatment. Therefore, it is important to evaluate changes in structure and mechanical properties in each treatment regimen of teriparatide compared to the placebo.

As a surrogate endpoint of the TOWER trial, computed tomography (CT) has been applied to evaluate and compare the effects of teriparatide versus placebo on proximal femur, since CT evaluation is considered to be a suitable cortical bone assessment. The purpose of this study was to investigate the effect of once-weekly injection of 56.5 μg teriparatide on bone geometry, volumetric bone density, and bone strength parameters of the proximal femur, using CT.

Methods {#Sec2}
=======

Subjects {#Sec3}
--------

Subjects in this study were a subset of the original TOWER trial \[[@CR5]\], and constituted ambulatory female patients with osteoporosis enrolled at 15 study sites equipped with multi-detector row CT (MDCT) to measure hip BMD, bone geometry, and biomechanical indices. All subjects in this study fulfilled the inclusion and exclusion criteria of the original TOWER trial. Subjects with one to five vertebral fractures with low BMD (T-score ≤ −1.67) at either the lumbar spine (L2--L4), femoral neck, total hip, or radius measured by dual-energy X-ray absorptiometry (DXA) or the right second metacarpal bone measured by radiographic absorptiometry were eligible. Subjects with diseases or using drugs affecting bone or calcium metabolism were excluded. The subjects were randomly divided into two groups, either weekly subcutaneous injection of 56.5 μg teriparatide or placebo for 72 weeks. All subjects received daily supplements of 610 mg calcium, 400 IU vitamin D~3,~ and 30 mg magnesium.

The original trial was conducted in compliance with the ethical principles stated in the Declaration of Helsinki and Good Clinical Practice. The trial was approved by the institutional review boards at each site and all subjects provided written informed consent before enrollment.

CT data acquisition {#Sec4}
-------------------

CT data were obtained at baseline and follow-up scans were performed at 48 and 72 weeks of treatment, using the scanning and reconstruction protocol previously described \[[@CR7]\]. The scanning conditions (X-ray energy, 120 to 140 kV; X-ray current, 250 mA; rotation speed, 0.8 to 1.0 s/rot; beam pitch, 0.5625 to 0.9375) and reconstruction parameters were predefined for each type of CT scanner. Beam pitch is defined as the ratio of table feed per rotation to the collimation, where collimation is the product of slice-thickness and the number of slices in each rotation. Field of View (FOV) was defined as 350 mm to cover bilateral proximal femur regions. In-plane spatial resolution of 0.625 to 0.652 mm and reconstructed slice thickness of 0.500 to 0.625 mm were adjusted according to CT scanner type. The CT values were converted to bone mineral scale by using a solid reference phantom, B-MAS200 (Fujirebio Inc., Tokyo, Japan) containing hydroxyapatite (HA) at 0, 50, 100, 150, and 200 mg/cm^3^.

The MDCT scanners used in this study originally included four Asteion 4, one Aquilion 16 TSX-101A, one Aquilion 32, and three Aquilion 64 scanners (Toshiba Medical Systems Corporation); two LightSpeed Ultra_16, one LightSpeed VCT_64, and one BrightSpeed Elite_16 scanner (GE-Yokogawa Medical); and one Somatom 16, and one Somatom 64 scanner (Siemens, AG).

Scanner cross-calibration {#Sec5}
-------------------------

Good linear correlations between the CT values and HA concentrations were demonstrated (*r* = 0.993 to 1.000; *p* \< 0.0006 to 0.0001) in all CT scanners. Differences in CT values according to X-ray energy were corrected using the reference phantom to convert CT values to HA equivalent values. However, it was necessary to confirm the longitudinal stability of the CT values of the threshold value used to define the cortical bone.

Quality assurance (QA) scans with a Type 3 Mindways Phantom (Mindways Software, Austin, TX, USA) were performed before and after study measurements took place at the individual clinical sites in order to adjust for longitudinal changes of the detector. QA measurements were evaluated according to the quantitated computed tomography (QCT)-Pro QA Guide from Mindways. There was no drift from baseline to the completion of treatment in any CT apparatus.

Subject positioning for CT scanning {#Sec6}
-----------------------------------

Subjects were scanned in the supine position with the reference phantom beneath them and placed so as to cover a region from the top of the acetabulum to 4 cm below the bottom of the lesser trochanter in each hip joint (average slice number was 298). Buffer material to protect artifact, such as a bolus bag or blanket, were placed between the subject and the CT calibration phantom. The subject's hands and arms were placed over their head or as high on the chest as was comfortable to avoid interfering with the scan area. The CT scanner table height was set to the center of the greater trochanter.

Analysis of BMD, bone geometry, and biomechanical properties obtained by CT {#Sec7}
---------------------------------------------------------------------------

Subject data were evaluated with QCT-Pro software v4.1.3 with the QCT-Pro Bone Investigational Toolkit v2.0 (BIT) (Mindways Software) for the femoral neck, inter-trochanter, and femoral shaft regions. All measurements were analyzed by a radiologist (M. Ito) blinded to treatment-group assignment.

QCT-Pro CTXA proximal femur exam analysis {#Sec8}
-----------------------------------------

The exact 3D rotation of the femur and the threshold setting for defining the bone contours appeared to be the two most critical steps for achieving accuracy and reproducibility in the automated procedures performed by QCT-Pro \[[@CR7], [@CR8]\]. The outer cortical margin was defined using uniform HA equivalent BMD values.

The femoral neck axis was identified visually and also automatically with the "Optimize FN Axis" algorithm. Using the eccentricity registration method, a series of 10 reformatted 1-mm slices was positioned perpendicularly to the neck axis. The definitions of inter-trochanter and femoral-shaft cross-section are consistent with the DXA-based hip structure analysis methods developed by Tom Beck \[[@CR9]\]. All steps were compared visually across all visits and repeated if the positioning did not appear to be accurate.

The eccentricity registration method was applied to define the volume of interest (VOI) consisting of six reformatted 1-mm slices oriented perpendicular to the neck axis. QCT BIT processing was then performed with a fixed-bone threshold for cortical separation set to 350 mg/cm^3^ for all subjects and visits. This application was used to measure hip axis length (HAL), femoral neck angle (FNA), and neck width, vBMD, cross-sectional area (CSA), and cross-sectional bone mass of the femoral neck, inter-trochanter, and femoral shaft (total and cortical regions). Cortical thickness and perimeter were also measured. Biomechanical properties were also derived from the cross-sectional parameters of the femoral neck, inter-trochanter, and shaft.

Analysis of cross-sectional bone geometry and volumetric BMD {#Sec9}
------------------------------------------------------------

The cross-sectional femoral neck data were based on the geometrical axis to calculate cortical CSA (in square centimeter), total CSA (in square centimeter), volumetric cortical BMD (cortical vBMD; in milligram per cubic centimeter), total volumetric BMD (total vBMD; in milligram per cubic centimeter), total bone mass (in gram), and cortical bone mass (in gram). In this study, total CSA was defined as the estimated total mineralized area. Cortical thickness (in millimeter) and cortical perimeter (in centimeter) were also derived.

Biomechanical parameters {#Sec10}
------------------------

Because biomechanical parameters were determined on the principal axis, the cross-sectional moment of inertia (CSMI; in millimeters to the fourth power), the section modulus (SM; in cubic millimeter) and the buckling ratio (BR) were calculated from bone density and geometrical data. The CSMI is defined by the integration of the products of incremental CSA and the square of their distance from the center of mass (centroid). The SM is the ratio of CSMI to the maximal distance of the material from the centroid, which is directly related to strength with respect to a corresponding bending stress. Due to local buckling, failure occurs on the compressive surface, and BR was calculated in this study as the maximal distance from the centroid divided by the average cortical thickness \[[@CR9]\].

Reproducibility of the analysis done by the QCT-Pro program was calculated by using five repeated measurements with visual matching each time from CT data sets without visible artifacts from seven healthy subjects. The coefficient of variation, as determined by the root mean square standard deviation divided by the mean, was 1.49 % for total vBMD, 2.63 % for cortical vBMD, 1.12 % for total mass, 1.71 % for total CSA, 2.11 % for cortical CSA, 2.11 % for cortical perimeter, and 3.58 % for cortical thickness at the femoral neck \[[@CR10]\].

Statistics {#Sec11}
----------

All statistical analyses were performed on subjects who had been randomized and had evaluable observations for QCT assessment both at baseline and post-dose (48 or 72 weeks). Paired and Student's *t* tests, and chi-square test were used and Pearson's correlation coefficients are shown. All *p* values calculated in the analysis were two-sided and were not adjusted for multiple testing. Statistical analyses were done with SAS version 9.1 (SAS Institute, Cary, USA).

Results {#Sec12}
=======

A total of 66 subjects were enrolled and randomly assigned to two treatment groups. There were 29 in the teriparatide group (age 66 to 83 years; mean ± SD, 74.2 ± 5.1 years) and 37 in the placebo group (age 66 to 88 years, 74.8 ± 5.3 years). Table [1](#Tab1){ref-type="table"} shows the background of subjects and bone characteristics at baseline in both groups. There were no significant differences between the two groups in age, height, weight, body mass index (BMI), years after menopause, BMD at the spine and hip, or the number of vertebral fractures (*p* \> 0.05).Table 1Subject baseline demographics and bone characteristicsTeriparatidePlacebo(*n* = 29)(*n* = 37)Age (years)74.2 ± 5.174.8 ± 5.3Body height (cm)147.8 ± 5.1147.5 ± 5.5Body weight (kg)50.9 ± 8.449.1 ± 8.5Body mass index (BMI) (kg/m^2^)23.3 ± 3.522.5 ± 3.5Years after menopause (years)24.6 ± 6.525.2 ± 6.6Bone mineral density (T-score) Lumbar spine (L2--4)−2.6 ± 1.0−2.8 ± 0.8 Femoral neck−2.4 ± 0.7−2.6 ± 0.7 Femoral total hip−2.0 ± 1.0−2.5 ± 1.2Number of prevalent vertebral fractures1.6 ± 1.11.3 ± 1.3Bone mineral density was measured by dual X-ray absorptiometryData are mean ± SDTwo subjects who were diagnosed with a BMD evaluation at the radius or metacarpal bone in the teriparatide group and one subject evaluated at the metacarpal bone in the placebo group were included

Effect of teriparatide on bone geometry parameters {#Sec13}
--------------------------------------------------

Baseline and the observed change of bone geometry parameters are shown in Table [2](#Tab2){ref-type="table"}. There were no significant differences at baseline for any bone geometry parameter at the femoral neck, inter-trochanter, and femoral shaft between the teriparatide and placebo groups. Compared to baseline, weekly teriparatide significantly increased cortical thickness at the femoral neck (3.5 %, 48 weeks) and shaft (2.6 %, 72 weeks). Cortical CSA increased at the inter-trochanter (3.8 %, 48 weeks) and femoral shaft (2.7 %, 72 weeks). Total CSA increased at the inter-trochanter (3.8 % at 48 weeks; 4.7 %, 72 weeks) and femoral shaft (2.5 %, 72 weeks). Cortical vBMD decreased at the femoral neck (1.2 %, 72 weeks) and inter-trochanter (1.5 %, 72 weeks). BR was also decreased at the femoral shaft (3.3 %, 72 weeks). There was no change in cortical perimeter at any site. There were no significant changes observed in the placebo group except for an increase in BR at the inter-trochanter (4.3 %, 48 weeks).Table 2Baseline QCT measurements and the percent changes at 48 and 72 weeksSiteParameterTeriparatidePlacebo(*n* = 29)(*n* = 37)Baseline48 weeks72 weeksBaseline48 weeks72 weeksFemoral neckCortical thickness (mm)1.47 ± 0.243.5 ± 7.1^\*^3.6 ± 9.01.52 ± 0.26−0.5 ± 6.8−0.9 ± 5.1Cortical CSA (cm^2^)0.86 ± 0.152.8 ± 7.62.2 ± 7.90.90 ± 0.15−0.6 ± 6.10.0 ± 5.2Total CSA (cm^2^)1.22 ± 0.212.2 ± 7.13.2 ± 7.31.28 ± 0.19−0.2 ± 5.10.6 ± 4.8Cortical perimeter (cm)10.96 ± 0.97−1.6 ± 4.4−1.4 ± 5.910.96 ± 0.930.2 ± 3.80.1 ± 3.5Cortical vBMD (mg/cm^3^)667.00 ± 52.57−0.6 ± 2.7−1.2 ± 2.3^\*^676.84 ± 46.65−0.2 ± 4.3−0.8 ± 3.1Total vBMD (mg/cm^3^)221.77 ± 31.771.0 ± 3.40.0 ± 3.8227.98 ± 35.35−0.7 ± 4.4−1.2 ± 3.3SM (cm^3^)0.38 ± 0.13.4 ± 8.22.3 ± 8.80.38 ± 0.1−0.3 ± 8.20.6 ± 7.5BR13.96 ± 2.32−3.2 ± 7.4−3.0 ± 8.313.44 ± 3.221.3 ± 6.21.8 ± 6.1Inter-trochanterCortical thickness (mm)1.43 ± 0.260.9 ± 5.90.7 ± 6.41.51 ± 0.29−2.3 ± 6.6−0.8 ± 7.7Cortical CSA (cm^2^)1.38 ± 0.293.8 ± 7.4^\*^2.9 ± 8.61.54 ± 0.33−1.6 ± 5.6−0.6 ± 5.5Total CSA (cm^2^)2.38 ± 0.453.8 ± 8.8^\*^4.7 ± 9.4^\*^2.59 ± 0.5−1.8 ± 5.6−0.6 ± 4.8Cortical perimeter (cm)16.76 ± 1.150.2 ± 3.3−0.6 ± 2.017.12 ± 1.180.6 ± 2.40.0 ± 2.1Cortical vBMD (mg/cm^3^)638.96 ± 48.01−0.4 ± 2.4−1.5 ± 2.1^\*\*^646.03 ± 44.09−0.3 ± 2.9−0.6 ± 2.4Total vBMD (mg/cm^3^)186.13 ± 35.971.1 ± 3.30.7 ± 4.7196.1 ± 35.7−1.5 ± 4.5−1.5 ± 4.8SM (cm^3^)0.67 ± 0.185.0 ± 15.84.1 ± 11.80.73 ± 0.182.4 ± 12.01.8 ± 10.2BR19.71 ± 3.62.1 ± 10.21.8 ± 10.719.26 ± 4.414.3 ± 9.5^\*^2.1 ± 10.1Femoral shaftCortical thickness (mm)3.71 ± 0.620.7 ± 5.12.6 ± 4.5^\*^3.91 ± 0.62−0.7 ± 4.6−1.3 ± 3.9Cortical CSA (cm^2^)2.22 ± 0.391.7 ± 5.22.7 ± 3.6^\*^2.35 ± 0.39−0.6 ± 4.1−0.5 ± 3.0Total CSA (cm^2^)2.38 ± 0.381.7 ± 5.02.5 ± 3.4^\*^2.5 ± 0.39−0.5 ± 4.0−0.1 ± 3.0Cortical perimeter (cm)10.27 ± 0.60.4 ± 3.8−0.7 ± 2.510.3 ± 0.70.2 ± 4.30.5 ± 3.2Cortical vBMD (mg/cm^3^)879.65 ± 70.770.4 ± 2.70.1 ± 3.6892.97 ± 59.030.3 ± 4.1−0.9 ± 3.1Total vBMD (mg/cm^3^)461.36 ± 77.370.7 ± 5.11.1 ± 5.7482.05 ± 74.95−0.2 ± 5.2−1.4 ± 4.3SM (cm^3^)0.88 ± 0.181.3 ± 5.92.7 ± 7.20.93 ± 0.2−0.8 ± 5.20.3 ± 4.8BR3.67 ± 0.88−0.4 ± 7.7−3.3 ± 5.4^\*^3.39 ± 0.750.9 ± 6.71.9 ± 5.3Data are mean ± SD*QCT* quantitated computed tomography, *CSA* cross-sectional area, *vBMD* volumetric bone mineral density, *SM* section modulus, *BR* buckling ratio^\*^ *p* \< 0.05; ^\*\*^ *p* \< 0.01 compared with baseline

Effect of teriparatide on cortical thickness, cortical and total CSA, and cortical perimeter compared to placebo {#Sec14}
----------------------------------------------------------------------------------------------------------------

Comparisons of cortical thickness, CSA, and perimeter between the two groups are shown in Fig. [1](#Fig1){ref-type="fig"}. Significantly higher cortical thickness was observed in the teriparatide group at the femoral neck (48 and 72 weeks) and shaft (72 weeks) (Fig. [1a](#Fig1){ref-type="fig"}). Significantly higher cortical CSA at the inter-trochanter (at 48 weeks) and at the femoral neck (72 weeks) were observed in the teriparatide group (Fig. [1b](#Fig1){ref-type="fig"}). Significantly higher total CSA at the inter-trochanter (48 and 72 weeks) and the femoral shaft (72 weeks) were observed in the teriparatide group (Fig. [1c](#Fig1){ref-type="fig"}). No significant differences were observed in the cortical perimeters between the teriparatide and placebo groups at any measurement site (Fig. [1d](#Fig1){ref-type="fig"}).Fig. 1Mean percent changes and 95 % confidence interval from baseline in cortical thickness (**a**), cortical cross-sectional area (*CSA*) (**b**), total CSA (**c**), and cortical perimeter (**d**) at 48 and 72 weeks of treatment with teriparatide and placebo. Changes at the femoral neck (*FN*), inter-trochanter (*IT*), and femoral shaft (*FS*) are shown. *Values on top of each panel* indicate *p* values (between teriparatide and placebo group). *Red* and *blue bars* correspond to teriparatide and placebo groups, respectively. To compare the difference between the two groups, the percent changes from baseline in QCT parameters were analyzed using the Student's *t* test

In summary, both cortical thickness and CSA increased in all three regions following treatment with teriparatide and decreased in the placebo group. In contrast, there was no change in cortical perimeter following once-weekly injections of teriparatide.

Effect of teriparatide on cortical and total vBMD compared to placebo {#Sec15}
---------------------------------------------------------------------

The comparison of cortical and total vBMD between the teriparatide and placebo groups is shown in Fig. [2](#Fig2){ref-type="fig"}. No significant differences in cortical vBMD were observed between the groups. A significant higher total vBMD in the teriparatide group was observed at the inter-trochanter (Fig. [2b](#Fig2){ref-type="fig"}).Fig. 2Mean percent changes and 95 % confidence interval from baseline in cortical volumetric bone mineral density (vBMD) (**a**) and total vBMD (**b**) at 48 and 72 weeks of treatment with teriparatide and placebo. Changes at the femoral neck (*FN*), inter-trochanter (*IT*), and femoral shaft (*FS*) are shown. *Values on top of each panel* indicate *p* values (between teriparatide and placebo group). *Red* and *blue bars* correspond to teriparatide and placebo groups, respectively. To compare the difference between the two groups, the percent changes from baseline in QCT parameters were analyzed using the Student's *t* test

Effect of teriparatide on biomechanical parameters compared to placebo {#Sec16}
----------------------------------------------------------------------

The differences in biomechanical parameters are shown in Fig. [3](#Fig3){ref-type="fig"}. SM changes in the teriparatide group at the three measurement sites were positive but not significant (Fig. [3a](#Fig3){ref-type="fig"}). BR values in the teriparatide group at the femoral neck (48 and 72 weeks) and shaft (72 weeks) were significantly lower compared to placebo (Fig. [3b](#Fig3){ref-type="fig"}).Fig. 3Mean percent changes and 95 % confidence interval from baseline in SM (**a**) and BR (**b**) at 48 and 72 weeks of treatment with teriparatide and placebo. Changes at the femoral neck (*FN*), inter-trochanter (*IT*), and femoral shaft (*FS*) are shown. *Values on top of each panel* indicate *p* values (between teriparatide and placebo group). *Red and blue bars* correspond to teriparatide and placebo groups, respectively. To compare the difference between the two groups, the percent changes from baseline in QCT parameters were analyzed using the Student's *t* test

Relationship between changes in cortical thickness and other parameters {#Sec17}
-----------------------------------------------------------------------

In order to understand the relationships between the parameters, the correlations between the percent changes in cortical thickness and those in the other parameters at the femoral neck at 72 weeks were analyzed, since cortical thickness was most significantly improved following once-weekly teriparatide treatment. Percent changes in cortical thickness at the femoral neck had significant positive correlations with percent change of cortical CSA (*r* = 0.612, *p* \< 0.0001), total CSA (*r* = 0.389, *p* = 0.0062), total vBMD (*r* = 0.546, *p* \< 0.0001), and SM (*r* = 0.523, *p* = 0.0001) in the teriparatide group. Negative correlations were found between percent changes of cortical thickness and cortical perimeter (*r* = −0.561, *p* \< 0.0001) or BR (*r* = −0.905, *p* \< 0.0001) in teriparatide group. The same trends in the correlation between cortical thickness and the other parameters were observed in placebo group. The correlation between percent change in cortical thickness and BR at the femoral neck was higher in the teriparatide group (*r*^2^ = 0.82) than in the placebo group (*r*^2^ = 0.54). There was no significant correlation between the percent change in cortical thickness and that of cortical vBMD in either group.

To visualize the relationships of multiple parameters at the individual level, the percent change in cortical thickness at the femoral neck was plotted on the horizontal axis of each panel in Fig. [4](#Fig4){ref-type="fig"} versus the percent changes in cortical CSA (Fig. [4a](#Fig4){ref-type="fig"}), perimeter (Fig. [4b](#Fig4){ref-type="fig"}), SM (Fig. [4c](#Fig4){ref-type="fig"}), and BR (Fig. [4d](#Fig4){ref-type="fig"}), separately for the teriparatide (solid lines) and placebo (dashed lines) groups. Each panel of Fig. [4](#Fig4){ref-type="fig"} is divided into four quadrants and the percentages of closed circles (teriparatide) and open circles (placebo) included in each quadrant are provided in the figure. The linear regression lines are basically the same between the teriparatide and placebo groups. Further, with respect to parameters with positive correlations (Fig. [4a, c](#Fig4){ref-type="fig"}), the distribution of individual data in the teriparatide group is significantly different from placebo (cortical CSA: *p* = 0.0111, SM: *p* = 0.0250); weighted distribution of closed circles (teriparatide) in the first quadrant is high, while the open circles (placebo) are highly distributed in the third quadrant. Similarly, in the case of parameters with negative correlations (Fig. [4b, d](#Fig4){ref-type="fig"}), the distribution of closed circles (teriparatide) in the fourth quadrant is high, while the open circles (placebo) are highly distributed in the second quadrant. The difference between teriparatide and placebo is significant for BR (*p* = 0.0274). These results suggest that changes in the placebo group with natural aging (i.e., age-related deteriorations in proximal femur geometry and biomechanical properties) are reversed at least partially by once-weekly teriparatide treatment.Fig. 4Weekly administration of teriparatide reverses age-related changes at 72 weeks in cortical geometry and biomechanical properties at the femoral neck. Relationships between percent changes in cortical thickness versus those in cortical cross-sectional area (*CSA*) (**a**), perimeter (**b**), SM (**c**), or BR (**d**) are shown. *Solid circles* and *open circles* correspond to percent changes of individuals in the teriparatide and placebo groups, respectively. Note that linear regression lines for teriparatide (*solid lines*) and placebo (*dashed lines*) showing the relationship between the percent change in cortical thickness and those in other parameters, are almost identical regardless of whether the correlation is positive (**a** and **c**) or negative (**b** and **d**). The distribution of *closed* and *open circles* in each quadrant is shown in percentages. Note that with respect to the parameters with positive correlations (**a** and **c**), the relative distribution of *open circles* (for placebo) in the third quadrant is shifted to the first quadrant by weekly teriparatide (*closed circles*). Similarly, in the case of the parameters with negative correlations (**b** and **d**), relative distribution of *open circles* (for placebo) in the second quadrant is shifted to the fourth quadrant by weekly teriparatide (*closed circles*), suggesting that weekly teriparatide reversed age-related changes in proximal femur geometry and biomechanical properties

Discussion {#Sec18}
==========

This longitudinal assessment by CT demonstrates the changes in bone geometry, vBMD, and mechanical properties at the proximal femur by once-weekly injection of 56.5 μg teriparatide for 72 weeks. This is the first longitudinal CT study to include comparison with a double-blinded placebo group. Previous studies have evaluated the effects of teriparatide on proximal femur geometry and its biomechanical properties using CT \[[@CR8]\], but they did not include a placebo group.

Generally, the effects of once-weekly teriparatide injection on proximal femur geometry in this study are similar to results with daily teriparatide injections reported in a subgroup of the EUROFORS study (EU-CT study) \[[@CR8]\]. The same analysis software program was employed and the main effects included increases in cortical thickness/CSA as well as total vBMD. Cortical thickness/CSA increasing while bone perimeter remained unchanged over 72 weeks of once-weekly teriparatide, suggests that cortical bone formation took place at the endosteal surface resulting in an increase in cortical thickness with a significant decrease in BR.

One difference observed between the weekly and daily treatment regimens is the effect on cortical vBMD. Although only eight patients were included in the treatment-naïve group in the EU-CT study, daily teriparatide decreased cortical vBMD at the femoral neck after 6 months of treatment (∼3.0 % from baseline), which was consistent with the results of a previous large clinical trial \[[@CR11]\]. Moreover, a decrease in cortical BMD at the femoral neck with 12 months of daily teriparatide treatment \[[@CR12]\] and a decrease in cortical BMD at the distal radius and tibia were reported \[[@CR13]\]. In contrast, our results showed that once-weekly teriparatide maintained cortical vBMD at the femoral neck (−0.6 %, 48 weeks and −1.2 %, 72 weeks). This difference may be due to distinct patterns of bone remodeling between daily and weekly teriparatide treatment given that weekly teriparatide caused an increase in serum osteocalcin (bone formation marker) and a decrease in urinary NTX (bone resorption marker) \[[@CR5]\]. Other factors such as cohort effects, differences in CT acquisition or the software may also have had an effect and help to explain the differences.

The question of whether or not teriparatide stimulates periosteal apposition has been raised. In the EU-CT study, total CSA (cortical CSA plus marrow area) did not change significantly throughout the study period and the authors concluded that there was no detectable periosteal apposition. DXA-based hip structure analysis (HSA), conducted as a subgroup of the Fracture Prevention Trial (DXA-HSA study) \[[@CR9]\], also showed that periosteal apposition appeared to be reduced in patients receiving daily teriparatide in comparison with a placebo-treated group. On the other hand, some studies reported daily treatment with teriparatide seemed to stimulate new bone formation on the periosteal and endosteal surfaces \[[@CR14], [@CR15]\]. Thus, periosteal and endosteal apposition may be stimulated within a certain time window or may vary depending on skeletal sites, such as weight bearing or non-weight bearing bone \[[@CR13]\].

Bone generally expands in diameter with age \[[@CR16], [@CR17]\], as less bone density requires a wider bone to maintain bending strength. It has been speculated that expansion is a homeostatic adaptation to a net bone loss in order to maintain bone strength \[[@CR18], [@CR19]\]. This age-related adaptive response was not seen in the placebo group of the current study. Once-weekly injection of teriparatide increased cortical thickness with no change in cortical perimeter at the femoral neck. Thus, it is tempting to speculate that as a result of increased cortical thickness (which improves bone strength), periosteal apposition may not be required under once-weekly teriparatide treatment. Actually, a change in BR based upon improvement in cortical thickness was observed in the teriparatide group. The *r*^2^ between percent change of cortical thickness and that of BR in the teriparatide group was higher than the placebo group.

As illustrated in Fig. [4](#Fig4){ref-type="fig"}, teriparatide improved all geometry and biomechanical parameters, while maintaining their relationships with changes in cortical thickness (as in the placebo group). However, the distribution patterns of their relationships indicate that the effect of teriparatide is in the exact opposite direction of age-related skeletal changes. It is suggested, therefore, that compared with the changes in the placebo group, once-weekly teriparatide injection reverses age-related deteriorations in bone structure and strength by increasing cortical thickness/CSA and total vBMD, not increasing cortical perimeter, and improving biomechanical parameters.

In our previous study which characterized femoral neck geometry in patients with hip versus trochanteric fractures and compared them with age-matched controls \[[@CR7]\], patients with femoral neck fracture had a significantly longer hip axis length (HAL), lower cross-sectional moment of inertia (CSMI), and higher BR, while those with trochanteric fractures had a smaller cortical CSA of the femoral neck. Once-weekly teriparatide may improve all these geometric changes. Taken together with the present results that SM (calculated as CSMI) divided by the maximal distance to center of the bone mass (centroid) increased by approximately 4 %, and BR decreased approximately 4 % compared to placebo, once-weekly injection of 56.5 μg teriparatide may have the potential to reduce the risk of hip fracture.

In the current longitudinal study, we also analyzed the geometry and biomechanical properties at the inter-trochanter and shaft regions in addition to those at the femoral neck. The percent changes in several parameters at the femoral neck and inter-trochanter were greater at 48 weeks compared to 72 weeks, while at the femoral shaft, the changes were greater at 72 weeks compared to 48 weeks, suggesting that the effects of teriparatide at the shaft take place in a later phase than those at the femoral neck and inter-trochanter. Endosteal bone formation might appear later at the purely cortical site, such as femoral shaft. Similar results were observed in the DXA-HSA study \[[@CR9]\], in which teriparatide seemed to have no significant effects on femoral shaft geometrical parameters.

A limitation of our study was the small number of subjects; since all the participating institutes in the TOWER trial were not equipped with MDCT scanners, the number of subjects with CT scans was limited. We paid careful attention, for example, to the CT images and those with artifacts were excluded from the study. However, the results of this study were proved by comparison with the placebo group. Another limitation was that we had no confirmation on the event of hip fracture, since no new hip fracture was reported in either group. As an additional limitation, Mindways software was used for analyzing the geometry of inner and outer surfaces of the cortex and this method may not currently be the best available technology for this evaluation. However, we carefully applied this program to define the same region of an individual subject for analysis, using the "Optimize FN Axis" algorithm. When this algorithm did not work well and different regions were obtained, we carefully manually adjusted both the axis of the femoral neck and the axis of the femoral shaft, visually comparing the baseline CT image and the treatment image. In addition, we improved the reproducibility using the eccentricity registration method for measurement of the femoral neck.

In conclusion, we have demonstrated (using CT and 3D analysis) that once-weekly teriparatide increased cortical thickness and cortical and total CSA, and improved biomechanical indices. Moreover, once-weekly teriparatide did not increase cortical perimeter but seemed to effectively reverse changes in proximal femur geometry with aging. Taken together with its anti-fracture efficacy in the spine \[[@CR5]\], once-weekly 56.5 μg teriparatide administration may have the potential to prevent hip fracture.
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